Acute and Persistent Hepatitis E Virus Genotype 3 and 4 Infection: Clinical Features, Pathogenesis, and Treatment

Area of Science:

• Hepatology
• Virology
• Infectious Diseases

Background:

• Hepatitis E virus (HEV) genotypes 3 and 4 are common in industrialized countries.
• Most HEV genotype 3 and 4 infections are asymptomatic, but can cause severe liver disease in certain populations.

Purpose of the Study:

• To summarize the clinical presentation and potential treatment of Hepatitis E virus genotypes 3 and 4 infections.
• To highlight the risks associated with HEV genotypes 3 and 4 in specific patient groups.

Main Methods:

• Review of existing literature on HEV genotypes 3 and 4.
• Analysis of clinical outcomes and therapeutic responses.

Main Results:

• HEV genotypes 3 and 4 can cause acute or acute-on-chronic liver failure, particularly in elderly men and those with pre-existing liver conditions.
• Immunosuppressed individuals, including transplant recipients and HIV-infected patients, are at risk for chronic hepatitis progressing to cirrhosis.
• Extrahepatic manifestations, such as neurological and renal diseases, can occur.
• Off-label ribavirin use shows promise in clearing chronic HEV infections and mitigating acute liver failure severity.

Conclusions:

• HEV genotypes 3 and 4 pose significant health risks, ranging from asymptomatic infection to life-threatening liver failure and cirrhosis.
• While no specific therapy is approved, ribavirin may be a viable treatment option for chronic HEV and severe acute cases.
• Early recognition and management are crucial, especially in immunocompromised patients and those with underlying liver disease.